Astellas Pharma (OTCPK:ALPMF) has submitted a
supplemental marketing application in Japan seeking approval to use
Evrenzo (roxadustat) to treat chronic kidney disease-associated anemia
in non-dialysis-dependent patients.
It is currently approved there for dialysis-dependent patients.
https://seekingalpha.com/news/3536362-astellas-files-application-in-japan-for-expanded-use-of-roxadustat
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.